DOI: 10.1002/rmb2.12358

SPECIAL REPORT

Reproductive Medicine and Biology

WILEY

Assisted reproductive technology in Japan: A summary report for 2018 by the Ethics Committee of the Japan Society of Obstetrics and Gynecology

Osamu Ishihara¹ | Seung Chik Jwa¹ | Akira Kuwahara² | Yukiko Katagiri³ | Yoshimitsu Kuwabara⁴ | Toshio Hamatani⁵ | Miyuki Harada⁶ | Yutaka Osuga⁶

¹Department of Obstetrics and Gynecology, Saitama Medical University, Saitama, Japan

²Department of Obstetrics and Gynecology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan

³Department of Obstetrics and Gynecology, Faculty of Medicine, Toho University, Tokyo, Japan

⁴Department of Obstetrics and Gynecology, Nippon Medical School, Tokyo, Japan

⁵Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo, Japan

⁶Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan

Correspondence

Seung Chik Jwa, Department of Obstetrics and Gynecology, Saitama Medical University, 38, Morohongo, Moroyama, Saitama 350-0495, Japan. Email: jwa_s@saitama-med.ac.jp

Funding information Health and Labor Sciences Research Grants

Abstract

Purpose: Since 2007, the Japan Society of Obstetrics and Gynecology (JSOG) has collected cycle-based data for assisted reproductive technology (ART) in an online registry. Here, we present the characteristics and treatment outcomes of ART cycles registered during 2018.

Methods: The Japanese ART registry consists of cycle-specific information for all ART treatment cycles implemented at 621 participating facilities. We conducted descriptive analyses for such cycles registered for 2018.

Results: In total, 454 893 treatment cycles and 56 979 neonates were reported in 2018: both increased from 2017. The mean maternal age was 38.0 years (standard deviation \pm 4.7). Of 247 402 oocyte retrievals, 118 378 (47.8%) involved freezeall-embryos cycles; fresh embryo transfer (ET) was performed in 50 463 cycles: a decreasing trend since 2015. A total of 199 914 frozen-thawed ET cycles were reported, resulting in 69 357 pregnancies and 49 360 neonates born. Single ET (SET) was performed in 82.2% of fresh transfers and 83.4% of frozen-thawed cycles, with singleton pregnancy/live birth rates of 97.2%/97.2% and 97.0%/97.2%, respectively. **Conclusions:** Total ART cycles and subsequent live births increased in 2018. SET was performed in over 80% of cases, and the mode of ET has shifted continuously from using fresh embryos to frozen-thawed ones compared with previous years.

KEYWORDS

ART registry, freeze-all strategy, in vitro fertilization, intracytoplasmic sperm injection, Japan Society of Obstetrics and Gynecology

1 | INTRODUCTION

Since the first baby in Japan conceived as a result of in vitro fertilization (IVF) was born in 1983, the number of assisted reproductive technology (ART) cycles has increased dramatically each year. According to the latest preliminary report from the International Committee Monitoring Assisted Reproductive Technologies for ART worldwide in 2016, Japan was the second largest user of ART worldwide in terms of the annual total number of treatment cycles performed.¹

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. Reproductive Medicine and Biology published by John Wiley & Sons Australia, Ltd on behalf of Japan Society for Reproductive Medicine.

4

TABLE 1 Trends in numbers of registered cycles, oocyte retrievals, pregnancies and neonates according to IVF, ICSI, and frozen-thawed embryo transfer cycles, Japan, 1985-2018

	Fresh cycles							
	, IVF ^a						ICSI ^b	
Year	No. of registered cycles	No. of egg retrieval	No. of freeze-all cycles	No. of ET cycles	No. of cycles with pregnancy	No. of neonates	No. of registered cycles	No. of oocyte retrievals
1985	1195	1195		862	64	27		
1986	752	752		556	56	16		
1987	1503	1503		1070	135	54		
1988	1702	1702		1665	257	114		
1989	4218	3890		2968	580	446		
1990	7405	6892		5361	1178	1031		
1991	11 177	10 581		8473	2015	1661		
1992	17 404	16 381		12 250	2702	2525	963	936
1993	21 287	20 345		15 565	3730	3334	2608	2447
1994	25 157	24 033		18 690	4069	3734	5510	5339
1995	26 648	24 694		18 905	4246	3810	9820	9054
1996	27 338	26 385		21 492	4818	4436	13 438	13 044
1997	32 247	30 733		24 768	5730	5060	16 573	16 376
1998	34 929	33 670		27 436	6255	5851	18 657	18 266
1999	36 085	34 290		27 455	6812	5870	22 984	22 350
2000	31 334	29 907		24 447	6328	5447	26 712	25 794
2001	32 676	31 051		25 143	6749	5829	30 369	29 309
2002	34 953	33 849		26 854	7767	6443	34 824	33 823
2003	38 575	36 480		28 214	8336	6608	38 871	36 663
2004	41 619	39 656		29 090	8542	6709	44 698	43 628
2005	42 822	40 471		29 337	8893	6706	47 579	45 388
2006	44 778	42 248		29 440	8509	6256	52 539	49 854
2007	53 873	52 165	7626	28 228	7416	5144	61 813	60 294
2008	59 148	57 217	10 139	29 124	6897	4664	71 350	69 864
2009	63 083	60 754	11 800	28 559	6891	5046	76 790	75 340
2010	67 714	64 966	13 843	27 905	6556	4657	90 677	88 822
2011	71 422	68 651	16 202	27 284	6341	4546	102 473	100 518
2012	82 108	79 434	20 627	29 693	6703	4740	125 229	122 962
2013	89 950	87 104	25 085	30 164	6817	4776	134 871	134 871
2014	92 269	89 397	27 624	30 414	6970	5025	144 247	141 888
2015	93 614	91 079	30 498	28 858	6478	4629	155 797	153 639
2016	94 566	92 185	34 188	26 182	5903	4266	161 262	159 214
2017	91 516	89 447	36 441	22 423	5182	3731	157 709	155 758
2018	92 552	90 376	38 882	20 894	4755	3402	158 859	157 026

Abbreviations: ET, embryo transfer; FET, Frozen-thawed embryo transfer; ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilization. ^aIncluding gamete intrafallopian transfer.

^bIncluding split-ICSI cycles.

-

^cIncluding cycles using frozen-thawed oocytes.

Because it is essential to monitor the trend and situations of ART treatments implemented in our country, in 1986 the Japan Society of Obstetrics and Gynecology (JSOG) began an ART registry system and launched an online registration system in 2007. Since then, cycle-specific information for all ART treatment cycles performed in ART facilities has been collected. The aim of this report is to describe the characteristics and treatment outcomes of registered ART cycles during 2018 in comparison with previous years.²

				FET cycles ^c			
No. of freeze- all cycles	No. of ET cycles	No. of cycles with pregnancy	No. of neonates	No. of registered cycles	No. of ET cycles	No. of cycles with pregnancy	No. of neonates
				184	92	7	3
				160	153	17	17
				369	352	57	39
	524	42	35	553	530	79	66
	1271	176	149	681	597	86	71
	4114	759	698	1303	1112	179	144
	7722	1732	1579	1682	1426	323	298
	11 269	2799	2588	2900	2676	449	386
	14 275	3495	3249	5208	4958	1086	902
	15 505	3952	3701	8132	7643	1748	1567
	18 592	4702	4247	9950	9093	2198	1812
	21 067	5240	4582	11 653	10 719	2660	2245
	23 058	5924	4862	13 034	11 888	3080	2467
	25 866	6775	5486	15 887	14 759	4094	3299
	27 895	7506	5994	24 459	19 641	6205	4798
	29 946	7768	5921	30 287	24 422	7606	5538
	30 983	8019	5864	35 069	28 743	9396	6542
	32 509	7904	5401	42 171	35 804	11 798	7930
11 541	34 032	7784	5194	45 478	43 589	13 965	9257
15 390	34 425	7017	4615	60 115	57 846	18 597	12 425
19 046	35 167	7330	5180	73 927	71 367	23 216	16 454
24 379	37 172	7699	5277	83 770	81 300	27 382	19 011
30 773	38 098	7601	5415	95 764	92 782	31 721	22 465
41 943	40 829	7947	5498	119 089	116 176	39 106	27 715
49 316	41 150	8027	5630	141 335	138 249	45 392	32 148
55 851	41 437	8122	5702	157 229	153 977	51 458	36 595
63 660	41 396	8169	5761	174 740	171 495	56 888	40 611
70 387	38 315	7324	5166	191 962	188 338	62 749	44 678
74 200	33 297	6757	4826	198 985	195 559	67 255	48 060
79 496	29 569	5886	4194	203 482	200 050	69 395	49 383

2 | MATERIALS AND METHODS

Since 2007, the JSOG has requested all participating ART clinics and hospitals to register cycle-specific information for all ART treatment

cycles. The information includes patient characteristics, information on the specific ART treatment, and pregnancy and obstetric outcomes. Detailed information collected in the registry has been reported previously.³ For ART cycles performed between January 1, 2018, and




FIGURE 1 Age distributions of all registered cycles, different subgroups of cycles for ET, pregnancy, and live birth in 2018. Adapted from the Japan Society of Obstetrics and Gynecology ART Databook 2018 (http://plaza.umin. ac.jp/~jsog-art/2018data 20201001. pdfwileyonlinelibrary.com]). ET, embryo transfer [Colour figure can be viewed at wileyonlinelibrary.com]

December 31, 2018, the JSOG requested registration of the information via an online registry system by the end of November 2019.

Using the registry data for 2018, we performed a descriptive analysis to investigate the characteristics and treatment outcomes of registered cycles. First, the numbers of registered cycles for the initiation of treatment, oocyte retrievals, fresh embryo transfer (ET) cycles, freezeall-embryos/oocytes cycles (henceforth "freeze-all"), frozen-thawed embryo transfer (FET) cycles, pregnancies, and neonates were compared with those in previous years. Second, the characteristics of registered cycles and treatment outcomes were described for fresh and FET cycles. Fresh cycles were stratified according to fertilization method including IVF, intracytoplasmic sperm injection (ICSI), gamete intrafallopian transfer (GIFT), and included cycles with oocyte freezing based on medical indications. Treatment outcomes included pregnancy, miscarriage, and live birth rates, multiple pregnancies defined according to the numbers of gestational sacs in utero and of neonates. Pregnancy outcomes included ectopic pregnancy, heterotopic pregnancy, artificially induced abortion, stillbirth, and fetal reduction. Third, the treatment outcomes of pregnancy, live birth, miscarriage, and multiple pregnancy rates were analyzed according to patient age. Last, we also recorded the treatment outcomes for FET cycles using frozen-thawed oocytes based on medical indications.

RESULTS 3

6

In Japan, there were 622 registered ART facilities in 2018, of which 621 participated in the ART registration system. A total of 592 registered facilities actually implemented some form of ART treatment in 2018 while 29 did not. Trends in the numbers of registered cycles, oocyte retrievals, pregnancies, and neonates born as a result of IVF, ICSI, and FET cycles from 1985 to 2018 are shown in Table 1. In 2018, 454 893 cycles were registered and 56 979 neonates were recorded. The total number of registered cycles for fresh IVF and ICSI followed by ET had decreased from the previous year in 2017. However, in 2018, the registered cycles and oocyte retrieval cycles increased from 2017 both for IVF and ICSI. Among registered fresh ET cycles, 63.2% were ICSI. The numbers of freeze-all cycles

increased both in IVF and ICSI cycles, so the numbers of neonates born after fresh ET cycles have been decreasing because of fewer such treatments. In contrast, the number of FET cycles increased continuously; in 2018, there were 203 482 (a 2.2% increase from 2017), resulting in 69 395 pregnancies and 49 383 neonates.

The distributions of patient age in registered cycles and different subgroups of cycles with ET, pregnancy, and live births are shown in Figure 1. The mean patient age for registered cycles was 38.0 years (standard deviation [SD] \pm 4.7), and 41.8% of registered cycles were for women in their 40s; the mean age for pregnancy and live birth cycles was 36.0 years (SD \pm 4.1) and 35.6 years (SD \pm 4.0), respectively.

The detailed characteristics and treatment outcomes of registered fresh cycles are shown in Table 2. There were 88 072 registered IVF cycles, 28 546 split-ICSI cycles, 127 974 ICSI cycles using ejaculated spermatozoa, 2339 ICSI cycles using testicular sperm extraction (TESE), 25 GIFT cycles, 644 cycles for oocyte freezing based on medical indications, and 3811 other cycles. Of the 247 402 cycles with oocyte retrieval, 118 378 (47.8%) were freeze-all cycles. The pregnancy rate per ET was 22.8% for IVF and 18.7% for ICSI using ejaculated spermatozoa. Single ET was performed at a rate of 82.2%, with a pregnancy rate of 21.4%. Live birth rates per ET were 15.9% for IVF, 12.7% for ICSI using ejaculated spermatozoa, and 11.3% for ICSI with TESE. The singleton pregnancy rate and live birth rate were 97.2% and 97.2%, respectively.

The characteristics and treatment outcomes of FET cycles are shown in Table 3. There were 203 246 registered cycles, among which FET was performed in 199 914, leading to 69 357 pregnancies (pregnancy rate per FET = 34.7%). The miscarriage rate per pregnancy was 25.5%, resulting in a 24.1% live birth rate per ET. Single ET was performed at a rate of 84.4%, and the singleton pregnancy and live birth rates were 97.0% and 97.2%, respectively.

Treatment outcomes of registered cycles, including pregnancy, miscarriage, live birth, and multiple pregnancy rates, according to maternal age, are shown in Table 4. Similarly, the distribution of pregnancy, live birth, and miscarriage rates according to maternal age are shown in Figure 2. The pregnancy rate per ET exceeded 40% up to 35 years of age; this rate gradually fell below 30% after age 40 and below 10% after age 45. The miscarriage rate was below 20% under age 35 years but gradually increased to 32.1% and

TABLE 2 Characteristics and treatment outcomes of registered fresh ART cycles in assisted reproductive technology, Japan, 2018

			ICSI					
	N/E ET	6	Ejaculated		OUET	Frozen		
Variables	IVF-ET	Split	sperm	TESE	GIFT	oocyte	Others ^a	Total
No. of registered cycles	88 072	28 546	127 974	2339	25	644	3811	251 411
No. of egg retrieval	86 021	28 267	126 422	2337	25	638	3692	247 402
No. of fresh ET cycles	20 403	5058	23 981	530	25	0	466	50 463
No. of freeze-all-embryos	37 116	19 728	58 454	1314	0	538	1228	118 378
No. of cycles with pregnancy	4648	1310	4487	89	4	0	103	10 641
Pregnancy rate per ET	22.8%	25.9%	18.7%	16.8%	16.0%	-	22.1%	21.1%
Pregnancy rate per egg retrieval	5.4%	4.6%	3.6%	3.8%	16.0%	-	2.8%	4.3%
Pregnancy rate per egg retrieval excluding freeze-all-embryos	9.5%	15.3%	6.6%	8.7%	16.0%	-	4.2%	8.3%
SET cycles	17 014	4449	19 292	340	2	-	402	41 499
Pregnancy following SET cycles	3933	1176	3624	58	0	-	92	8883
Rate of SET cycles	83.4%	88.0%	80.5%	64.2%	8.0%	-	86.3%	82.2%
Pregnancy rate following SET cycles	23.1%	26.4%	18.8%	17.1%	0.0%	-	22.9%	21.4%
Miscarriages	1161	273	1229	28	0	-	20	2711
Miscarriage rate per pregnancy	25.0%	20.8%	27.4%	31.5%	0.0%	-	19.4%	25.5%
Singleton pregnancies ^b	4408	1256	4247	85	3	-	98	10 097
Multiple pregnancies ^b	113	29	143	1	0	-	3	289
Twin pregnancies ^b	109	29	142	1	0	-	3	284
Triplet pregnancies ^b	4	0	1	0	0	-	0	5
Quadruplet pregnancies ^b	0	0	0	0	0	-	0	0
Multiple pregnancy rate ^b	2.5%	2.3%	3.6%	1.2%	0.0%	-	3.0%	2.8%
Live births	3246	965	3045	60	3	-	78	7397
Live birth rate per ET	15.9%	19.1%	12.7%	11.3%	12.0%	-	16.7%	14.7%
Total number of neonates	3319	983	3150	61	3	-	80	7596
Singleton live births	3164	947	2926	59	3	-	76	7175
Twin live births	76	18	112	1	0	-	2	209
Triplet live births	1	0	0	0	0	-	0	1
Quadruplet live births	0	0	0	0	0	-	0	0
Pregnancy outcomes						-		
Ectopic pregnancies	59	20	56	0	1	-	1	137
Heterotopic pregnancy	0	0	0	0	0	-	0	0
Artificial abortions	25	5	25	1	0	-	1	57
Still births	18	4	5	0	0	-	0	27
Fetal reductions	1	0	0	0	0	-	0	1
Unknown cycles for pregnancy outcomes	104	32	121	0	0	-	3	260

Abbreviations: ET, embryo transfer; GIFT, gamete intrafallopian transfer; ICSI, intracytoplasmic sperm injection; IVF-ET; in vitro fertilization-embryo transfer; SET, single embryo transfer; TESE, testicular sperm extraction.

^aOthers including zygote intrafallopian transfer (ZIFT).

^bSingleton, twin, triplet and quadruplet pregnancies were defined according to the numbers of gestational sacs in utero.

49.9% for those aged 40 and 43 years, respectively. The live birth rate per registered cycle was around 20% up to 33 years of age and decreased to 9.5% and 3.1% at ages 40 and 43 years, respectively. Multiple pregnancy rates varied between 2% and 3% across most age groups.

The treatment outcomes of cycles using frozen-thawed oocytes based on medical indications are shown in Table 5. There were 136 such FET cycles, among which 38 cycles resulted in a pregnancy (pregnancy rate per FET = 27.9%). The miscarriage rate per pregnancy was 29.0%, resulting in a 15.4% live birth rate per ET.

Reproductive Medicine and Biolog

8

TABLE 3 Characteristics and treatment outcomes of FET cyclesin ART clinics in Japan for 2018

Variables	FET	Others ^a	Total
No. of registered cycles	202 229	1017	203 246
No. of FET	199 022	892	199 914
No. of cycles with pregnancy	69 072	285	69 357
Pregnancy rate per FET	34.7%	32.0%	34.7%
SET cycles	167 898	743	168 641
Pregnancy following SET cycles	59 899	242	60 141
Rate of SET cycles	84.4%	83.3%	83.4%
Pregnancy rate following SET cycles	35.7%	32.6%	35.7%
Miscarriages	17 601	69	17 670
Miscarriage rate per pregnancy	25.5%	24.2%	25.5%
Singleton pregnancies ^b	65 556	266	65 822
Multiple pregnancies ^b	2015	9	2024
Twin pregnancies ^b	1980	8	1988
Triplet pregnancies ^b	31	1	32
Quadruplet pregnancies ^b	3	0	3
Multiple pregnancy rate ^b	3.0%	3.3%	3.0%
Live births	47 873	208	48 081
Live birth rate per FET	24.1%	23.3%	24.1%
Total number of neonates	49 148	212	49 360
Singleton live births	46 432	200	46 632
Twin live births	1335	6	1341
Triplet live births	14	0	14
Quadruplet live births	1	0	1
Pregnancy outcomes			
Ectopic pregnancies	350	1	351
Heterotopic pregnancy	9	0	9
Artificial abortions	272	0	272
Still births	236	1	237
Fetal reduction	16	0	16
Unknown cycles for pregnancy outcomes	1999	3	2002

Abbreviations: FET, frozen-thawed embryo transfer; SET, single embryo transfer.

^aIncluding cycles using frozen-thawed oocyte.

^bSingleton, twin, triplet and quadruplet pregnancies were defined according to the numbers of gestational sacs in utero.

4 | DISCUSSION

Using the current Japanese ART registry system for JSOG, there were 454 893 registered ART cycles and 56 979 resultant neonates, The total number of initiated fresh cycles (both IVF and ICSI) increased from the previous year. Freeze-all cycles predominated, accounting for 47.8% of all initiated fresh cycles. The single ET rate was 82.2% for fresh transfers and 83.4% for frozen-thawed cycles, which also showed an increasing trend since 2007, reaching a single-ton live birth rate of 97% in total. These results represent the latest clinical practice of ART in Japan.

Advanced age for women receiving ART remains one of the most important factors for the increased number of ART cycles in Japan. Thus, in 41.8% of registered cycles, women were in their 40s, similar to the previous year (41.9%), but decreased somewhat from 2015 (43.4%). This might be attributed to the encouragement offered to younger couples having infertility problem to enter ART programs; the Japanese government provides incentives for women under 40s to receive six subsidies for ART to reduce the economic burden, whereas women aged 40-42 can only receive a subsidy for three attempts. There is currently an upper limit of 73 000 000 JPY per household for the subsidies, but this policy might be changed because of the recent stagnation of the Japanese total fertility rate (TFR). The latest TFR of Japan for 2019 was 1.36,⁴ which had decreased from 1.42 in 2018.⁵ Establishment of effective policies for reversing this low TFR is an urgent problem in Japan's society.

The number of registered ART cycles, both fresh and frozen ET, increased from 2017 to 2018, but the numbers of neonates born in fresh ET cycles have been decreasing since 2016, mostly attributed to the decreased numbers of fresh ET cycles and increased numbers of freeze-all cycles in Japan. As a result, more than 47% of fresh cycles were freeze-all in Japan in 2018. This strategy is beneficial for avoiding complications related to ovarian stimulation, such as ovarian hyperstimulation syndrome (OHSS), especially in high-risk patients such as those with polycystic ovary syndrome or high ovarian reserve.⁶ Supraphysiological hormonal environment in fresh ET cycles might affect endometrial receptivity and implantation rate.⁷ However, clinical evidence on the effect of a freeze-all strategy for women with regular menstrual cycles is conflicting.⁸⁻¹⁰ A recently published meta-analysis including 11 randomized controlled trials (RCTs) with 5379 patients reported that freeze-all and subsequent elective FET demonstrated that importantly, neither the live birth rate (relative risk, RR 1.03, 95% confidence interval [CI], 0.91-1.17) in the subgroup of normal responders nor the cumulative live birth rate in the entire population (RR 1.04, 95% CI, 0.97-1.11) were significantly different between the two groups.⁷ On the other hand, a more recent multicenter RCT investigating the effect of blastocyst-stage ET after freeze-all or fresh ET cycles among 825 ovulatory women from China demonstrated that a freeze-all strategy with subsequent elective FET achieved a significantly higher live birth rate than did fresh blastocyst ET (RR 1.26, 95% CI, 1.14-1.41).⁸ The mean age of participants was 28.8 years both for the fresh and frozen ET groups, and the mean number of aspirated oocytes was 14. Thus, we should be cautious when extrapolating these results to the Japanese population. A recent multicenter RCT conducted in Europe investigated the effect of freeze-all and fresh

matrix	No of										
6 3 0 0 5 500 6.1% 00% 1 1 0 0 1 125% 34% 00% 4 22 2 1 1 125% 34% 155% 136% 7 3 2 5 5 473% 25% 153% 153% 10 31 1 1 1 1 1 15% 153% 10 31 1 1 1 1 1 1 1 1 11 11 11 1 <t< th=""><th>registered cycles</th><th>No. of ET cycles</th><th>Pregnancy</th><th>Multiple pregnancies^a</th><th>Miscarriage</th><th>Live birth</th><th>Pregnancy rate per ET</th><th>Pregnancy rate per registered cycles</th><th>Live birth rate per registered cycles</th><th>Miscarriage rate per pregnancy</th><th>Multiple pregnancy rate^a</th></t<>	registered cycles	No. of ET cycles	Pregnancy	Multiple pregnancies ^a	Miscarriage	Live birth	Pregnancy rate per ET	Pregnancy rate per registered cycles	Live birth rate per registered cycles	Miscarriage rate per pregnancy	Multiple pregnancy rate ^a
8 1 0 0 1 12.55 3.4% 0.0% 74 22 2 4.3.8% 21.4% 15.5% 15.6% 15.6% 7 3 2 3 2 4.3.8% 21.4% 15.5% 15.6% 7 3 1 1 5 4.3.8% 22.6% 15.6% 15.6% 7 4.9 23.1 1 4.9% 24.9% 21.4% 15.5% 17.01 4.6 24.9% 24.9% 24.9% 21.4% 15.5% 17.01 4.6 24.9% 24.9% 26.5% 21.4% 15.5% 17.01 4.9% 4.4% 26.5% 21.4% 15.5% 15.5% 9.01 10.9 4.4% 26.5% 21.4% 15.5% 15.6% 9.01 10.9 4.4% 26.5% 21.4% 15.5% 15.6% 9.01 10.9 4.4% 26.5% 21.4% 15.6% 15.6%	49	9	ю	0	0	ო	50.0%	6.1%	6.1%	0.0%	0.0%
48 21 2 3 16 45.86 21.46 15.56 15.66 73 33 2 5 43.36 22.656 16.86 13.36 710 35 1 1 15 32.55 15.95 15.35 710 80 13 11 15 45.75 25.55 12.45 15.35 1101 455 13 71 49.75 25.55 21.05 15.36 1110 145 13 14.95 25.53 21.05 15.76 15.76 1110 145 24.95 25.45 21.05 15.76 15.76 1125 100 560 34.16 27.45 21.95 15.76 11257 54.35 24.36 25.35 24.36 21.66 15.76 11557 64.31 27.45 21.56 21.56 15.76 15.76 11557 51.30 12.45 21.46 21.66 12.66 </td <td>29</td> <td>80</td> <td>1</td> <td>0</td> <td>0</td> <td>1</td> <td>12.5%</td> <td>3.4%</td> <td>3.4%</td> <td>0.0%</td> <td>0.0%</td>	29	80	1	0	0	1	12.5%	3.4%	3.4%	0.0%	0.0%
79 35 2 4.3% 2.2.6% 16.8% 1.3% 700 731 7 4.9% 2.5% 2.4% 1.3% 710 7 7 7.4% 2.5% 2.14% 1.5% 1010 800 13 7.3 4.7% 2.5% 2.1% 1.5% 1108 800 13 7.3 4.5% 2.5% 2.1% 1.5% 11076 7.4% 7.4% 2.5% 2.1% 1.5% 1.5% 11075 800 7.2 8.4% 2.5% 2.1% 1.5% 11075 832 101 7.3 2.4% 2.1% 1.5% 11075 832 101 4.7% 2.7% 2.1% 1.5% 11075 832 116 4.7% 2.7% 1.5% 1.5% 11075 843 7.1% 7.1% 7.1% 1.5% 1.5% 11075 843 7.1% 7.1% 7.1%	103	48	22	7	с	16	45.8%	21.4%	15.5%	13.6%	9.5%
203 98 1 1 15 82 478% 25.4% 21.4% 15.3% 1018 445 13 13 147 449% 24.9% 14.3% 14.3% 1018 445 13 13 43.9% 25.4% 21.2% 15.5% 1148 148 23 23.9% 14.3% 25.4% 21.8% 15.5% 6459 23.16 74 24.8% 25.4% 21.8% 15.7% 6451 342 13.6% 24.3% 25.4% 21.8% 15.7% 6453 3670 142 24.3% 27.4% 21.8% 15.7% 6453 143 24.3% 24.3% 27.4% 21.8% 17.0% 15274 62.29 117 47.3% 27.4% 21.8% 17.6% 15274 62.19 17.4% 21.8% 21.8% 21.8% 21.8% 15274 52.19 11.7% 21.8% 21.8% 21.8%	155	79	35	7	S	26	44.3%	22.6%	16.8%	14.3%	5.7%
514 231 0 33 17 4.9% 24.9% 13.1% 14.3% 1018 4.65 18 7.2 4.7% 2.5.% 21.2% 15.5% 11780 800 13 128 6.37 6.4.% 2.5.3% 21.0% 15.5% 4354 2316 7.3 4.5% 2.5.3% 21.0% 15.5% 6951 3072 0.19 9.4 4.5% 2.5.3% 21.0% 15.5% 6951 3072 100 9.0 14.1% 2.4.5% 2.1.9% 15.5% 10755 46.32 117 2.4.5% 2.7.4% 2.1.6% 15.5% 11075 64.30 9.17 4.4.5% 2.7.4% 2.1.9% 17.6% 11075 64.31 7.3 4.3.4% 2.7.4% 2.1.3% 17.6% 11075 64.31 7.3 2.7.4% 2.1.3% 2.1.6% 17.6% 11075 64.31 7.3 2.7.4% 2.1.6% <td>384</td> <td>205</td> <td>98</td> <td>1</td> <td>15</td> <td>82</td> <td>47.8%</td> <td>25.5%</td> <td>21.4%</td> <td>15.3%</td> <td>1.0%</td>	384	205	98	1	15	82	47.8%	25.5%	21.4%	15.3%	1.0%
1018 465 18 72 57.% 56.% 21.2% 15.% 1780 800 13 128 49.% 25.3% 21.0% 16.0% 3148 738 23.9 1188 47.3% 23.6% 21.0% 16.1% 6951 2016 7.3 55.6% 21.0% 21.0% 16.1% 6951 3972 100 580 36.15 45.3% 21.3% 16.9% 10755 4632 117 786 34.1% 27.4% 21.1% 17.6% 11267 6432 117 743 24.3% 23.4% 21.1% 17.6% 11274 643 134 24.1% 24.3% 25.3% 13.7% 13.7% 11537 6431 743 24.3% 25.3% 13.7% 24.3% 11546 6431 743 24.3% 25.3% 13.5% 24.3% 11546 6431 743 24.3% 25.3% 13.5%<	926	514	231	0	33	177	44.9%	24.9%	19.1%	14.3%	0.0%
1780 800 13 128 6.3 4.9% 2.6.3% 2.10% 16.0% 3148 1488 32 239 118 7.3% 28.6% 22.9% 16.1% 4859 2216 74 348 7.4% 21.6% 15.7% 15.7% 4859 2216 74 346 24.5% 27.4% 21.6% 15.7% 4850 2090 107 46.9 31.7% 21.6% 15.7% 15.6% 10551 3672 117 76 31.4% 27.4% 21.6% 16.6% 117346 671 137 44.7% 27.4% 21.6% 16.8% 117346 671 1350 44.8 27.3% 17.6% 16.8% 117346 6714 1350 40.8% 25.3% 20.3% 16.8% 117346 6714 135 40.8% 27.3% 17.1% 23.3% 117346 6714 137 40.8% 25.3	1757	1018	465	18	72	372	45.7%	26.5%	21.2%	15.5%	4.0%
3148 148 2 2 1 4 5 2 5 6 1 6 1 6 1 6 1 6 1 6 1 6 1 6 1 6 1 6 1 6 1 <td>3037</td> <td>1780</td> <td>800</td> <td>13</td> <td>128</td> <td>639</td> <td>44.9%</td> <td>26.3%</td> <td>21.0%</td> <td>16.0%</td> <td>1.7%</td>	3037	1780	800	13	128	639	44.9%	26.3%	21.0%	16.0%	1.7%
4859 216 74 348 15.6 27.4% 21.6% 15.7% 6931 3090 92 518 20.0 45.6% 27.8% 21.6% 16.8% 8825 3872 100 680 3011 43.9% 27.4% 21.6% 16.8% 10755 4632 117 7.66 36.15 41.2% 27.3% 21.9% 17.6% 112921 5429 137 40.8 26.4% 26.3%	5199	3148	1488	32	239	1188	47.3%	28.6%	22.9%	16.1%	2.2%
6951 3090 92 518 240 $4,5$ % $27,8$ % 21.6 % 16.8 % 8826 3872 100 680 301 4.9 % 27.4 % 21.3 % 17.6 % 10755 4522 117 786 3615 4.3 % 27.4 % 21.3 % 17.6 % 12921 5428 135 987 4122 200 % 25.4 % 200 % 18.2 % 15237 6229 176 1171 4732 408 25.3 % 116.6 % 18.2 % 17346 6714 252 1171 4732 408 % 25.3 % 117.6 % 22.9 % 17346 6714 252 1171 4732 408 % 25.3 % 117.6 % 22.9 % 117346 6714 252 1172 407 % 32.7 % 117.6 % 22.9 % 118399 6813 217 1784 20.2 % 116.6 % 25.6 % 11989 6814 717 1787 21.8 % 21.8 % 11989 6917 1096 472 21.9 % 21.8 % 21.8 % 11980 910 126 1918 37.7 % 12.4 % 21.8 % 22.9 % 11980 910 126 118 12.8 % 12.8 % 12.8 % 22.9 % 11980 910 126 126 % 12.8 % 12.8 % 21.8 % 21.8 % 11980 910 126 126 126 % 12.4 % 12.8 % 21.8 % 11980	8098	4859	2216	74	348	1763	45.6%	27.4%	21.8%	15.7%	3.4%
8826 3872 100 680 301 43.9% 27.4% 21.3% 17.6% 10755 46.32 117 786 3615 4.1.8 27.1% 17.0% 17.6% 112921 54.38 135 987 41.22 4.0.8 26.4% 20.0% 18.2% 15257 62.39 17.6 1171 47.32 40.8% 25.3% 19.2% 18.8% 17346 6714 222 1520 16.0% 47.8% 25.3% 13.6% 23.9% 17346 6714 272 16.0% 47.8% 25.3% 13.1% 23.9% 17346 6714 272 14.9% 25.3% 13.1% 23.9% 11939 611 173 47.3% 23.1% 13.9% 23.9% 11939 641 201 17.8% 23.9% 13.9% 23.9% 11939 641 203 41.9% 23.1% 13.9% 23.9% 23.9%	11 128	6951	3090	92	518	2407	44.5%	27.8%	21.6%	16.8%	3.0%
10755 4632 117 786 3615 43.1% 21.1% 17.0% 12921 548 135 987 41.2 42.0% 26.4% 20.0% 18.2% 15257 629 176 1171 47.32 40.8% 25.3% 19.2% 18.6% 15756 627 157 1578 18.6% 20.1% 17346 6714 252 1528 40.4% 36.7% 17.5% 23.9% 17346 6714 252 1528 40.4% 36.7% 23.7% 17.5% 23.9% 17346 671 197 1460 47.8 36.7% 13.9% 23.9% 19833 641 197 1460 47.8 36.7% 13.9% 23.9% 1168 641 17 14.9% 24.7% 13.9% 24.7% 117285 3339 91 1467 19.3% 14.8% 7.1% 24.9% 117285 3339 9	14 116	8826	3872	100	680	3011	43.9%	27.4%	21.3%	17.6%	2.6%
12 72 12 987 4122 20,4% 20,6% 18.2% 15 57 6229 176 1171 47.32 40.8% 25.3% 19.2% 18.6% 15 57 221 1350 5002 40.4% 25.3% 19.2% 18.6% 17 446 171 4732 40.8% 25.3% 17.1% 20.3% 17 447 252 1528 4848 38.7% 25.3% 17.1% 23.3% 18 6813 217 1787 24.2% 13.9% 23.3% 19 993 6813 217 14.3% 24.3% 25.3% 15.4% 26.3% 215 9949 464 126 17.8% 24.3% 26.3% 26.3% 215 919 201 1606 47.8% 27.7% 14.3% 26.3% 215 919 916 17.8% 15.1% 14.8% 26.3% 26.3% <t< td=""><td>17 101</td><td>10 755</td><td>4632</td><td>117</td><td>786</td><td>3615</td><td>43.1%</td><td>27.1%</td><td>21.1%</td><td>17.0%</td><td>2.6%</td></t<>	17 101	10 755	4632	117	786	3615	43.1%	27.1%	21.1%	17.0%	2.6%
15 57 629 176 1171 4732 $40.8%$ $55.3%$ $19.2%$ $18.6%$ $18.6%$ $16 639$ 677 211 1350 5002 $40.4%$ $25.0%$ $18.6%$ $20.1%$ 17346 6714 252 1528 4848 $38.7%$ $23.7%$ $17.1%$ $22.8%$ $18 393$ 6711 197 1606 4778 $36.5%$ $22.1%$ $15.7%$ $23.9%$ $18 933$ 6813 217 1787 $23.9%$ $13.9%$ $23.9%$ $23.9%$ $19 833$ 6813 217 1787 $23.9%$ $23.9%$ $23.9%$ 21516 5969 162 1789 478 $25.2%$ $13.9%$ $23.9%$ 21516 5969 162 1789 478 $21,9%$ $23.9%$ $23.9%$ 21516 5969 162 1789 $23.9%$ $12.9%$ $23.9%$ $23.9%$ 21516 5969 162 1791 2736 $21.4%$ $21.4%$ $23.9%$ 21516 2339 126 2336 $12.4%$ $21.4%$ $23.9%$ $23.9%$ 17289 5339 970 276 5336 $14.9%$ $6.3%$ $23.%$ $23.%$ 13072 1946 57 276 $23.9%$ $14.9%$ $23.%$ $21.4%$ $23.%$ 17289 5337 116 $14.9%$ $6.3%$ $21.4%$ $21.9%$ $23.%$ 13070 194 57 126 $21.6%$ $21.4%$ <td< td=""><td>20 594</td><td>12 921</td><td>5428</td><td>135</td><td>987</td><td>4122</td><td>42.0%</td><td>26.4%</td><td>20.0%</td><td>18.2%</td><td>2.6%</td></td<>	20 594	12 921	5428	135	987	4122	42.0%	26.4%	20.0%	18.2%	2.6%
16639 6727 211 1350 5002 $40.4%$ $25.0%$ $18.6%$ $20.1%$ 17346 6714 252 1528 4848 $38.7%$ $23.7%$ $17.1%$ $23.9%$ 18333 6711 197 1606 4778 $3.5%$ $23.7%$ $15.7%$ $23.9%$ 18333 6813 217 1606 4778 $3.5%$ $22.1%$ $15.7%$ $23.9%$ 18393 6813 217 1787 $23.1%$ $15.7%$ $23.9%$ $23.9%$ 21644 6917 203 2049 4521 $31.9%$ $21.7%$ $23.6%$ 21560 5969 162 1918 $37.3%$ $11.8%$ $23.5%$ $23.6%$ 17600 162 1761 178 $25.6%$ $31.9%$ $23.1%$ $23.1%$ 171261 5969 162 2164 $12.4%$ $12.4%$ $23.7%$ $23.6%$ 171263 3339 914 126 1764 $19.3%$ $23.7%$ $23.7%$ 171263 1946 576 2056 $23.6%$ $23.8%$ $21.4%$ $23.7%$ 171263 1946 576 1676 $23.8%$ $12.4%$ $21.4%$ $23.9%$ 171263 1946 576 1676 $23.7%$ $12.4%$ $21.4%$ $23.7%$ 171263 1946 566 1266 $12.6%$ $12.4%$ $21.4%$ $21.4%$ $12,0101212022414.9%20.9%21.9%$	24 600	15257	6229	176	1171	4732	40.8%	25.3%	19.2%	18.8%	2.9%
17346 6714 252 1528 4848 $38.7%$ $23.7%$ $171%$ $22.8%$ 18393 6711 197 1606 4778 $36.5%$ $22.1%$ $15.7%$ $23.9%$ 19893 6813 217 1606 4778 $36.5%$ $22.1%$ $15.7%$ $23.9%$ 19893 6813 217 1787 2476 $13.9%$ $24.5%$ $24.5%$ $24.5%$ 21646 5969 162 1918 3733 $27.7%$ $15.1%$ $95.%$ $24.6%$ 21510 5969 162 1718 2176 $15.1%$ $95.%$ $24.6%$ 19608 4664 126 1768 $23.8%$ $12.4%$ $71.%$ $37.9%$ 17285 3339 91 1465 1674 $12.4%$ $12.6%$ $32.1%$ 17286 3333 91 126 176 $23.8%$ $12.4%$ $71%$ $37.9%$ 17285 3339 91 126 1768 $23.6%$ $12.4%$ $17.%$ $37.9%$ 13072 1946 57 972 877 $14.9%$ $53.%$ $17.%$ $53.4%$ 13072 1946 57 972 877 $14.9%$ $53.%$ $17.%$ $54.9%$ 13072 1946 57 976 $32.%$ $12.%$ $17.%$ $54.9%$ 13072 151 12 167 $12.%$ $12.%$ $12.%$ $12.%$ 1200 156 167 $16.%$ $12.%$	26 892	16 639	6727	211	1350	5002	40.4%	25.0%	18.6%	20.1%	3.2%
18 393 6711 197 1606 4778 36.5% 22.1% 15.7% 23.9% 19 893 6813 217 1787 4670 3.42% 20.2% 13.9% 23.9% 2164 6917 203 2049 4521 31.9% 20.2% 13.9% 24.6% 21616 5969 162 1918 3733 27.7% 15.1% 9.5% 24.6% 21510 5969 162 1916 3733 27.7% 15.1% 9.5% 32.4% $17 285$ 3339 91 126 1768 2563 23.8% 12.4% 7.1% 37.9% $17 285$ 3339 91 126 1768 2665 23.8% 12.4% 7.1% 37.9% $13 072$ 1946 57 972 837 14.9% 8.7% 9.3% 4.7% 4.7% $13 072$ 1946 57 972 877 14.9% 6.8% 9.3% 1.7% 9.9% $13 072$ 1946 57 972 972 972 972 972 972 976 5235 419 57 972 972 976 976 976 976 5236 116 1956 926 926 926 926 926 926 $13 070$ 151 126 126 126 126 926 926 $13 070$ 126 126 126 126 126 926	28 339	17 346	6714	252	1528	4848	38.7%	23.7%	17.1%	22.8%	3.8%
19893 6813 217 1787 4570 $34.2%$ $20.2%$ $13.9%$ $26.2%$ 21684 6917 203 2049 4521 $31.9%$ $18.1%$ $11.8%$ $26.6%$ 21610 5969 162 1918 3733 $27.7%$ $15.1%$ $9.5%$ $29.6%$ 21510 5964 126 1768 3733 $27.7%$ $15.1%$ $9.5%$ $32.1%$ 19608 4664 126 1768 2565 2338 $12.4%$ $7.1%$ $37.9%$ 17285 3339 91 1465 1768 $23.8%$ $12.4%$ $7.1%$ $37.9%$ 17286 530 176 2655 2338 $12.4%$ $7.1%$ $37.9%$ $37.9%$ 13072 1946 57 970 266 350 $14.6%$ $6.8%$ $3.1%$ $4.7%$ 13072 970 297 216 320 $14.6%$ $2.1%$ $14.9%$ $56.4%$ 13072 149 56 320 $14.6%$ $3.2%$ $1.7%$ $59.4%$ 2740 151 2 254 146 $0.7%$ $50.6%$ 2740 151 2 20 $3.2%$ $1.0%$ $0.7%$ $50.6%$ 1289 56 1 14 $1.0%$ $0.1%$ $0.1%$ $50.6%$ 1280 10 10 10 10 10 $0.1%$ $0.1%$ $0.1%$ 1280 10 10 10 10 10 $0.$	30 377	18393	6711	197	1606	4778	36.5%	22.1%	15.7%	23.9%	3.0%
21684 6917 203 2049 4521 $31.9%$ $18.1%$ $11.8%$ $29.6%$ 21510 5969 162 1918 3733 $27.7%$ $15.1%$ $9.5%$ $29.6%$ 19608 4664 126 1918 3733 $27.7%$ $15.1%$ $9.5%$ $32.1%$ 17285 3339 91 1465 1674 $19.3%$ $12.4%$ $7.1%$ $37.9%$ 17285 3339 91 1465 1674 $19.3%$ $9.3%$ $4.7%$ $43.9%$ 13072 1946 57 972 972 8877 $14.9%$ $6.8%$ $3.1%$ $4.9%$ 13072 1946 57 972 972 817 $14.9%$ $6.8%$ $3.1%$ $4.9%$ 13072 1946 57 970 256 2387 $14.9%$ $6.8%$ $3.1%$ $4.9%$ 5235 419 57 970 586 $3.2%$ $1.1%$ $1.7%$ $58.4%$ 2740 151 2 256 167 $3.2%$ $1.1%$ $0.7%$ $59.6%$ 2128 56 1 37 $1.4%$ $3.2%$ $1.1%$ $0.7%$ $59.6%$ 2128 56 1 $3.7%$ $1.6%$ $0.7%$ $0.7%$ $59.6%$ 2128 56 1 $1.6%$ $1.6%$ $0.7%$ $0.7%$ $0.6%$ 1010 10 1 10 $1.4%$ $0.7%$ $0.7%$ $0.7%$ 1011 10 10 <	33 679	19 893	6813	217	1787	4670	34.2%	20.2%	13.9%	26.2%	3.3%
21510 5969 162 1918 3733 $277%$ $15.1%$ $9.5%$ $32.1%$ 19608 4664 126 1768 2665 $23.8%$ $12.4%$ $31.9%$ $37.9%$ 17285 3339 91 1465 1674 $19.3%$ $9.3%$ $4.7%$ $43.9%$ 17285 3339 91 1465 1674 $19.3%$ $6.8%$ $4.7%$ $43.9%$ 13072 1946 57 972 877 $14.9%$ $6.8%$ $4.7%$ $4.9%$ 8397 970 29 566 350 $11.6%$ $4.8%$ $1.7%$ $54.%$ 5235 419 5 256 350 $11.6%$ $4.8%$ $1.7%$ $59.6%$ 5236 151 2 90 54 $1.4%$ $0.7%$ $59.6%$ 2740 151 2 90 54 $1.4%$ $0.7%$ $56.6%$ 1289 56 11 $4.3%$ $1.4%$ $0.7%$ $59.6%$ 1289 56 11 11 $4.3%$ $1.4%$ $0.7%$ $59.6%$ 1289 56 11 1.7 $4.3%$ $1.4%$ $0.7%$ $59.6%$ 1289 56 1 1.7 $4.3%$ $1.0%$ $0.7%$ $59.6%$ 1289 56 1 1.7 $1.4%$ $0.7%$ $0.4%$ $50.6%$ 108 10 1.7 1.7 $1.4%$ $0.7%$ $0.7%$ $59.6%$ 1289 10 1.7 1.9	38 256	21 684	6917	203	2049	4521	31.9%	18.1%	11.8%	29.6%	3.0%
19608 4664 126 1768 2665 $23.8%$ $12.4%$ $71%$ $37.9%$ 17285 3339 91 1465 1674 $19.3%$ $9.3%$ $4.7%$ $43.9%$ 17202 1946 57 972 877 $14.9%$ $6.8%$ $3.1%$ $43.9%$ 13072 1946 57 972 877 $14.9%$ $6.8%$ $3.1%$ $43.9%$ 8397 970 29 566 350 $11.6%$ $6.8%$ $3.1%$ $43.9%$ 5235 419 56 254 $3.2%$ $1.7%$ $58.4%$ 2740 151 2 254 $14.6%$ $3.2%$ $1.1%$ 2740 151 2 972 $14.6%$ $3.2%$ $0.7%$ 1289 56 1 3 $1.6%$ $1.4%$ $0.7%$ $59.6%$ 1280 56 1 317 $4.3%$ $1.4%$ $0.7%$ $6.1%$ 522 17 11 11 6 $3.3%$ $1.0%$ $0.7%$ $6.1%$ 301 8 0 1 12 12 12 $0.3%$ $0.7%$ $0.3%$ 128 10 10 10 10 10 $0.7%$ $0.7%$ $0.7%$ 128 10 10 10 10 10 $0.7%$ $0.7%$ $0.7%$ 128 10 10 10 10 10 $0.7%$ $0.7%$ $0.7%$ 129 10 10 10 10 </td <td>39 410</td> <td>21 510</td> <td>5969</td> <td>162</td> <td>1918</td> <td>3733</td> <td>27.7%</td> <td>15.1%</td> <td>9.5%</td> <td>32.1%</td> <td>2.8%</td>	39 410	21 510	5969	162	1918	3733	27.7%	15.1%	9.5%	32.1%	2.8%
17 285 3339 91 1465 1674 19.3% 9.3% 4.7% 43.9% 13 072 1946 57 972 877 14.9% 6.8% 9.1% 49.9% 13 072 1946 57 972 877 14.9% 6.8% 43.9% 8397 970 29 566 350 11.6% 4.8% 1.7% 58.4% 8397 970 29 566 350 11.6% 4.8% 1.7% 58.4% 5235 419 5 8.0% 3.2% 1.1% 58.4% 2740 151 2 254 145 8.0% 5.7% 6.6% 2740 151 2 9.0% 0.7% 59.6% 56.6% 1289 56 1 1 1 1.4% 0.4% 6.6% 2740 151 1 4.3% 1.4% 0.4% 6.6% 128 1 1 1 1.4	37 736	19 608	4664	126	1768	2665	23.8%	12.4%	7.1%	37.9%	2.8%
13 072 19 46 57 972 877 14.9% 6.8% 3.1% 49.9% 83 97 970 29 566 350 11.6% 4.8% 5.8.4% 83 97 970 29 566 350 11.6% 4.8% 5.8.4% 5235 419 5 254 145 8.0% 3.2% 1.1% 60.6% 2740 151 2 254 145 8.0% 3.2% 1.1% 60.6% 1289 56 1 43 1.4% 0.7% 6.1% 1280 151 1 14 4.3% 1.4% 0.4% 6.1% 522 17 1 11 6.3% 1.4% 0.3% 6.1% 513 17 1 1.0% 0.3% 0.4% 6.1% 513 17 1 1.0% 0.3% 0.3% 6.1% 514 5 3 2.0% 0.4% 0.4%	35 860	17 285	3339	91	1465	1674	19.3%	9.3%	4.7%	43.9%	2.8%
8397 970 29 566 350 11.6% 4.8% 1.7% 58.4% 5235 419 5 254 145 8.0% 3.2% 1.1% 58.4% 2740 151 2 90 54 5.5% 2.0% 0.7% 59.6% 1289 56 1 37 17 4.3% 1.4% 0.4% 56.6% 1289 56 1 37 17 4.3% 1.4% 0.4% 59.6% 1289 56 1 37 17 4.3% 1.4% 0.4% 66.1% 522 17 1 11 6 3.3% 1.0% 0.3% 64.7% 301 8 0 5 3 2.7% 0.3% 65.5% 224 5 0 0 8 0.3% 0.3% 0.3%	28 715	13 072	1946	57	972	877	14.9%	6.8%	3.1%	49.9%	3.0%
5235 419 5 254 145 8.0% 3.2% 1.1% 60.6% 2740 151 2 90 54 5.5% 2.0% 0.7% 59.6% 1289 56 1 37 17 4.3% 1.4% 0.4% 60.4% 522 17 1 7 3.3% 1.0% 0.3% 64.7% 301 8 0 5 3 2.7% 0.3% 62.5% 224 5 0 1 2 2.2% 0.7% 0.3% 62.5%	20 212	8397	970	29	566	350	11.6%	4.8%	1.7%	58.4%	3.1%
2740 151 2 90 54 5.5% 2.0% 0.7% 59.6% 1289 56 1 37 17 4.3% 1.4% 0.4% 66.1% 522 17 1 11 6 3.3% 1.0% 0.3% 64.7% 301 8 0 5 3 2.7% 0.8% 63.5% 224 5 0 1 2 2.2% 0.7% 50.0%	13 187	5235	419	Ŋ	254	145	8.0%	3.2%	1.1%	60.6%	1.2%
1289 56 1 37 17 4.3% 1.4% 0.4% 66.1% 522 17 1 11 6 3.3% 1.0% 0.3% 64.7% 301 8 0 5 3 2.7% 0.8% 0.3% 62.5% 224 5 0 1 2 2.2% 0.7% 0.3% 20.0%	7480	2740	151	7	60	54	5.5%	2.0%	0.7%	59.6%	1.4%
522 17 1 11 6 3.3% 1.0% 0.3% 64.7% 301 8 0 5 3 2.7% 0.8% 6.3% 64.7% 301 8 0 5 3 2.7% 0.8% 6.3% 65.5% 224 5 0 1 2 2.2% 0.7% 0.3% 20.0%	3994	1289	56	1	37	17	4.3%	1.4%	0.4%	66.1%	1.9%
301 8 0 5 3 2.7% 0.8% 0.3% 62.5% 224 5 0 1 2 2.2% 0.7% 0.3% 20.0%	1776	522	17	1	11	9	3.3%	1.0%	0.3%	64.7%	6.3%
224 5 0 1 2 2.2% 0.7% 0.3% 20.0%	666	301	80	0	5	ო	2.7%	0.8%	0.3%	62.5%	0.0%
	705	224	5	0	1	2	2.2%	0.7%	0.3%	20.0%	0.0%

 TABLE 4
 Treatment outcomes of registered cycles according to patient age, Japan, 2018

9

Abbreviation: ET, embryo transfer. ^aMultiple pregnancies were defined according to the numbers of gestational sacs in utero.




FIGURE 2 Pregnancy, live birth, and miscarriage rates, according to patient age, among all registered cycles in 2018. Adapted from the Japan Society of Obstetrics and Gynecology ART Databook 2018 (http://plaza.umin. ac.jp/~jsog-art/2018data_20201001. pdfwileyonlinelibrary.com]). ET, embryo transfer [Colour figure can be viewed at wileyonlinelibrary.com]

Variables	Embryo transfer using frozen-thawed oocytes
No. of registered cycles	236
No. of ET	136
No. of cycles with pregnancy	38
Pregnancy rate per ET	27.9%
SET cycles	91
Pregnancy following SET cycles	22
Rate of SET cycles	66.9%
Pregnancy rate following SET cycles	24.2%
Miscarriages	11
Miscarriage rate per pregnancy	29.0%
Singleton pregnancies ^a	30
Multiple pregnancies ^a	4
Twin pregnancies ^a	4
Triplet pregnancies ^a	0
Quadruplet pregnancies ^a	0
Multiple pregnancy rate ^a	11.8%
Live births	21
Live birth rate per ET	15.4%
Total number of neonates	23
Singleton live births	19
Twin live births	2
Triplet live births	0
Quadruplet live births	0
Pregnancy outcomes	
Ectopic pregnancies	0
Heterotopic pregnancy	0
Artificial abortions	0
Still births	0
Fetal reduction	0
Unknown cycles for pregnancy outcomes	2

Abbreviations: ET, embryo transfer; SET, single embryo transfer.

^aSingleton, twin, triplet and quadruplet pregnancies were defined according to the numbers of gestational sacs in utero.

TABLE 5 Treatment outcomes of embryo transfers using frozen-thawed oocytes based on medical indications in ART clinics in Japan, 2018

11

blastocyst ET strategies with a gonadotropin releasing hormone agonist used to trigger final oocyte maturation among 460 women with regular menstrual cycles (mean age of participants 32.4 years in the freeze-all group and 32.3 years in fresh ET group) demonstrated that the ongoing pregnancy rate, live birth rate, and obstetric and neonatal complications did not differ between the two groups. The study concluded that their findings warrant caution in the indiscriminate application of a freeze-all strategy when there is no apparent risk of OHSS.¹⁰

The strength of the Japanese ART registry is its mandatory reporting system with a high compliance rate, in cooperation with the government subsidy system. Using this system, nearly all participating ART facilities (621 of 622 facilities) have registered cycle-specific information, so selection bias caused by a lack of participation in the registration system is unlikely. Nevertheless, several limitations exist in the registry. First, it includes only cycle-specific information, so it is very difficult to identify cycles in the same patient using the registry in its current format. Given recent Japanese ART practice, in which nearly half of all initiated cycles are freeze-all, widely used indicators such as pregnancy and live birth rates per aspiration cycle will be affected markedly, which could mislead public opinion regarding the quality of treatment as ET was not performed in most included fresh ART cycles.¹¹ It has been suggested recently that the cumulative live birth rate per oocyte aspiration is more suitable when reporting the success rate of ART outcomes.^{12,13} Because the Japanese ART registry has asked for frozen cycles to include identification numbers for fresh cycles since 2014, using the information the cumulative live birth rate per aspiration might be informative in the future for Japan as nearly half of all cycles are freeze-all. Second, the Japanese ART registry includes unfertilized oocyte freezing cycles only for medically indicated cases, such as fertility preservation in cancer patients (Tables 2 and 5); the registry does not include cycles with non-medical indications: so to speak, "social oocyte freezing." Because no other registration system currently exists for oocyte freezing, there is no information available for such cycles. Third, the registry includes several patient background factors for each cycle such as body mass index, numbers of previous pregnancies and parity, but the high missed reporting rate for those variables makes it impossible to adjust for them to calculate the success rate for ART in Japan.

In conclusion, our analysis of the ART registry for 2018 demonstrated that the total number of ART cycles increased from the previous year. SET was performed at a rate of more than 82%, resulting in a 97% singleton live birth rate. Although an increasing trend for frozen ET and freeze-all cycles is evident Japan, further investigation is required to evaluate the effect of the freeze-all strategy and frozen ET on cumulative live births, particularly with respect to maternal and neonatal safety issues. These data represent the latest clinical practices of ART in Japan. Further improvements in the ART registration system in Japan are important.

ACKNOWLEDGEMENTS

We thank all of the registered facilities for their cooperation in providing their responses. We would also like to encourage these facilities to continue promoting use of the online registry system and assisting us with our research. We thank James Cummins, PhD, from Edanz Group (https://en-author-services.edanzgroup.com/ac) for editing a draft of this manuscript. This study was supported by Health and Labor Sciences Research Grants.

eproductive Medicine and Biology

DISCLOSURES

Conflict of interest: There is no conflict of interest regarding the publication of this study. *Human rights statement and informed consent*: All procedures were performed in accordance with the ethical standards of the relevant committees on human experimentation (institutional and national) and the Helsinki Declaration of 1964 and its later amendments. *Animal rights*: This report does not contain any studies performed by any of the authors that included animal participants.

ETHICAL APPROVAL

Not applicable.

ORCID

Seung Chik Jwa (Dhttps://orcid.org/0000-0002-8815-5714 Yukiko Katagiri (Dhttps://orcid.org/0000-0002-0052-896X

REFERENCES

- Adamson GD, et al.International Committee for Monitoring Assisted Reproductive Technology: world report on assisted reproductive technology, 2016. 2020. https://secureservercdn. net/198.71.233.47/3nz.654.myftpupload.com/wp-content/uploa ds/ICMART-ESHRE-WR2016-FINAL-20200901.pdf Accessed September 13, 2020.
- Ishihara O, Jwa SC, Kuwahara A, et al. Assisted reproductive technology in Japan: a summary report for 2016 by the Ethics Committee of the Japan Society of Obstetrics and Gynecology. *Reprod Med Biol.* 2019;18:7-16.
- 3. Irahara M, et al. Assisted reproductive technology in Japan: a summary report of 1992–2014 by the Ethics Committee, Japan Society of Obstetrics and Gynecology. *Reprod Med Biol.* 2017;16:126-132.
- Ministry of Health Labour and Welfare. Summary of vital statistics in 2019 Tokyo. 2020. https://www.mhlw.go.jp/toukei/saikin/hw/ jinkou/kakutei19/dl/02_kek.pdf. Accessed September 13, 2020
- Ministry of Health Labour and Welfare. Summary of vital statistics in 2018 Tokyo. 2019. https://www.mhlw.go.jp/toukei/saikin/hw/ jinkou/kakutei18/dl/02_kek.pdf. Accessed September 13, 2020
- Chen ZJ, et al. Fresh versus frozen embryos for infertility in the polycystic ovary syndrome. N Engl J Med. 2016;375:523-533.
- Roque M, et al. Fresh versus elective frozen embryo transfer in IVF/ ICSI cycles: a systematic review and meta-analysis of reproductive outcomes. *Hum Reprod Update*. 2019;25:2-14.
- Wei D, et al. Frozen versus fresh single blastocyst transfer in ovulatory women: a multicentre, randomised controlled trial. *Lancet*. 2019;393:1310-1318.
- 9. Vuong LN, et al. IVF transfer of fresh or frozen embryos in women without polycystic ovaries. N Engl J Med. 2018;378:137-147.
- 10. Stormlund S, et al. Freeze-all versus fresh blastocyst transfer strategy during in vitro fertilisation in women with regular

menstrual cycles: multicentre randomised controlled trial. *BMJ*. 2020;370:m2519.

- 11. Adamson GD, et al. International Committee for Monitoring Assisted Reproductive Technology: world report on assisted reproductive technology, 2011. *Fertil Steril*. 2018;110:1067-1080.
- 12. Maheshwari A, McLernon D, Bhattacharya S. Cumulative live birth rate: time for a consensus? *Hum Reprod*. 2015;30:2703-2707.
- 13. Malizia BA, Hacker MR, Penzias AS. Cumulative live-birth rates after in vitro fertilization. *N Engl J Med.* 2009;360:236-243.

How to cite this article: Ishihara O, Jwa SC, Kuwahara A, et al. Assisted reproductive technology in Japan: A summary report for 2018 by the Ethics Committee of the Japan Society of Obstetrics and Gynecology. *Reprod Med Biol.* 2021;20:3–12. <u>https://doi.org/10.1002/rmb2.12358</u>